Pricing updated 2019-04-24. Prices are subject to change without notice.
CP 101,606 is a noncompetitive antagonist of NDMA receptors containing the NR2B subunit (Kd = 4.2 nM).1 CP 101,606 is highly selective for NR1/NR2B-containing NMDA receptors over NR1, NR2A, and NR2B subunits alone and NR1/NR2A receptors in HEK293 cell homogenates. In vivo, CP 101,606 (30 mg/kg, s.c.) inhibits mechanical hyperalgesia following carrageenan challenge in rats.2 It also inhibits licking behavior in rats induced by capsaicin (Item No. 92350) and phorbol-12-myristate-13-acetate (PMA; Item No. 10008014; ED50s = 7.5 and 5.7 mg/kg, respectively). CP 101,606 reverses catalepsy in rats induced by haloperidol (Item No. 12014) with an ED50 value of 0.4 mg/kg.3 CP 101,606 (1 mg/kg, s.c.) alone or in combination with L-DOPA methyl ester (Item No. 16149) temporarily improves parkinsonian symptoms in an MPTP model of Parkinson's disease in rhesus monkeys.
Warning - this product is not for human or veterinary use.
View the Cayman Structure Database for chemical structure definitions for many Cayman products
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data pack, and GC-MS data.
Chazot, P.L., Lawrence, S., and Thompson, C.L. Studies on the subtype selectivity of CP-
Taniguchi, K., Shinjo, K., Mizutani, M., et al. Antinociceptive activity of CP-